News Search Results
Aug 28, 2025, 19:44 ET Everest Medicines Announces Interim Results for First Half of 2025
issued share capital of I-Mab, inclusive of ordinary shares already held by Everest, making us I-Mab's largest single shareholder. I-Mab is a global biotechnology company focused on precision immunotherapy for cancer. This strategic equity investment in I-Mab further advances our global pipeline of next-generation
More news about: Everest Medicines
Aug 28, 2025, 17:46 ET Global Pharmaceutical Contract Manufacturing Market to Surpass the USD 360 Billion Mark by 2032 | DelveInsight
CommercialPharmaceutical Contract Manufacturing Market Segmentation By End-Users: Biopharmaceutical and Pharmaceutical Companies, Biotechnology Companies, and OthersPharmaceutical Contract Manufacturing Market Segmentation By Geography: North America,
More news about: DelveInsight Business Research, LLP
Aug 28, 2025, 12:54 ET 27th Edition Global Family Office Investment Summit Returns to the French Riviera Under the Patronage of H.E. David Lisnard, Mayor of Cannes
The Rise of Global AI and Future Tech LeadershipSustainable Infrastructure & Renewable EnergyHealthcare, Biotechnology & Longevity innovationsPhilanthropy, Family Legacy & GovernanceReal Estate, Private Equity & Global MarketsCross-Border
More news about: Ritossa Family Office
Aug 28, 2025, 12:10 ET Aircraft Engine Forging Market to reach US$5,966.9 million by 2031; Growth Due to Growing Demand from Aviation Industry | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials.
More news about: The Insight Partners
Aug 28, 2025, 11:04 ET Draper Names Space Kinetic Corp. the Newest DraperSPARX Partner
meet our customers' requirements. These efforts focus on four critical mission areas: Strategic Systems, Space Systems, Electronic Systems, and Biotechnology Systems. To extend our legacy into the future, the
More news about: Draper Laboratory
Aug 28, 2025, 10:45 ET Life Science Tools Market to Grow at a CAGR of 10.81% from 2025 to 2032 | SkyQuest Technology Consulting
The life science tools market is experiencing robust growth, primarily driven by increased investments in biomedical research, the expansion of biotechnology and pharmaceutical industries, and rising demand for personalized medicine and genomics-based diagnostics. The surge in chronic diseases, infectious
More news about: SkyQuest Technology
Aug 28, 2025, 10:10 ET Amines Market Size to Reach USD 26.55 Billion by 2035 | CAGR 4.55% | Vantage Market Research
Autoimmune Diseases, Others) by End Use (Hospitals & Clinics, Diagnostic Laboratories, Research & Academic Institutes, Pharmaceutical & Biotechnology Companies, Blood Banks & Organ Transplant Centers, Home Care Settings, Veterinary Clinics & Diagnostic Labs) by Region (North
More news about: Vantage Market Research
Aug 28, 2025, 09:28 ET Made Scientific Launches Scientific Advisory Board with Appointments of Distinguished Cell Therapy Innovators Miguel Forte, M.D., Ph.D., Paul K. Wotton, Ph.D., Shishir Gadam, Ph.D., and Young K. Hong, M.D.
the global expertise and resources of GC Corporation of South Korea, a global leader in the pharmaceutical and biotechnology sectors.
More news about: Made Scientific, Inc.
Aug 28, 2025, 09:00 ET Evommune to Participate in Three Upcoming Investor Conferences
Calif., Aug. 28, 2025 /PRNewswire/ -- Evommune, Inc., a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that the company will participate
More news about: Evommune, Inc
Aug 28, 2025, 09:00 ET D3 Bio, Inc. Announces FDA Breakthrough Therapy Designation and Orphan Drug Designation for D3S-001 for the Treatment of Patients with KRAS G12C-Mutated Cancers
with KRASG12C mutations: a phase 1 trial. Nat Med. 2025 Aug;31(8):2768-2777.About D3 Bio D3 Bio is a global biotechnology company focused on the discovery, development, and registration of new medicines in oncology and immunology. The company's discovery and development
More news about: D3 Bio, Inc.
Aug 28, 2025, 08:35 ET Stramsen Biotech Submits Pre-IND Package to FDA for SBX 1977 Wound Care Medicine, Requests Pre-IND Meeting and Phase 2 Trial
upcoming clinical trials and underscores our commitment to addressing critical healthcare needs. Stramsen is a venture backed plant-based biotechnology company with safe and advanced wound healing solutions and 32 other drug candidates for infectious and noninfectious diseases. This Pre-IND package
More news about: Stramsen Biotech Inc
Aug 28, 2025, 08:30 ET Oncolytics Biotech® Announces Upcoming Investor Conferences in September
[email protected]. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated promising results
More news about: Oncolytics Biotech® Inc.
Aug 28, 2025, 08:30 ET Halozyme to Participate at Upcoming Investor Conferences
at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Aug 28, 2025, 08:30 ET Webinar on Vaccine Access Policy: Navigating Change Under the Trump Administration, Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Aug 28, 2025, 08:30 ET Innovations in Alzheimer's Disease Clinical Trials: Digital Endpoints - Upcoming Expert Panel Discussion Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Aug 28, 2025, 08:00 ET IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies
Sana Biotechnology (NASDAQ: SANA),
More news about: Flagship Pioneering
Aug 28, 2025, 07:05 ET REGENXBIO to Participate in Upcoming Investor Conferences
the webcast will be available for approximately 30 days following the presentation. ABOUT REGENXBIO Inc. REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Aug 28, 2025, 07:03 ET Veeva Announces Collaboration with Global Biotech to Further Accelerate Clinical Trial Innovation
Veeva Systems (NYSE: VEEV) today announced a collaboration with Amgen to advance clinical trial innovation. As a global leader in biotechnology, Amgen will employ the Veeva Clinical Platform
More news about: Veeva Systems
Aug 28, 2025, 07:03 ET Veeva Announces Collaboration with Global Biotech to Further Accelerate Clinical Trial Innovation
Veeva Systems (NYSE: VEEV) today announced a collaboration with Amgen to advance clinical trial innovation. As a global leader in biotechnology, Amgen will employ the Veeva Clinical Platform
More news about: Veeva Systems
Aug 28, 2025, 07:00 ET SmartLabs and Sonrai Launch Exclusive Partnership to Bring Advanced AI Capabilities to SmartLabs' Member Companies
Sonrai Discovery, expedites identifying and developing drug or therapeutic targets, improving patient outcomes through AI. The company partners with biotechnology and pharmaceutical companies to manage and analyze their precision medicine data. By leveraging Sonrai Discovery, these companies can confidently
More news about: SmartLabs
Aug 28, 2025, 07:00 ET SmartLabs and Sonrai Launch Exclusive Partnership to Bring Advanced AI Capabilities to SmartLabs' Member Companies
Sonrai Discovery, expedites identifying and developing drug or therapeutic targets, improving patient outcomes through AI. The company partners with biotechnology and pharmaceutical companies to manage and analyze their precision medicine data. By leveraging Sonrai Discovery, these companies can confidently
More news about: SmartLabs
Aug 28, 2025, 06:59 ET Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference
Aug. 28, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that
More news about: Q32 Bio
Aug 28, 2025, 06:12 ET More than 500 MNCs offered record 5000 Job Offers to Engineering students of Chandigarh University in 2024-25
Wonder Cement. In Biotechnology and Food Technology, 75% students of Chandigarh University received job offers from over 20 companies during the campus placement drive with the highest package of Rs 7 LPA. The top recruiters for Biotechnology and Food Technology
More news about: Chandigarh University
Aug 28, 2025, 03:30 ET Leucid Bio to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
Aug. 28, 2025 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company's proprietary lateral CAR platform,
More news about: Leucid Bio
Aug 27, 2025, 19:45 ET Ascletis Announces Favorable and Differentiated Pharmacokinetic Profile of ASC30 Oral Once-Daily Tablet in Its U.S. Phase Ib Multiple Ascending Dose Study
patent protection until 2044 without patent extensions. About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.